Voyager Acquisition Corp.

Benzinga · Jun 10, 2026

VERAXA Biotech And Voyager Acquisition Complete Business Combination; On June 11, 2026, VERAXA Will Commence Trading Its Shares Under The Symbol "VRXA"

Business combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed, innovative biopharmaceutical company focused on next-generation cancer therapies of novel bispecific T-cell engagers

Yahoo · Mar 2, 2026

VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.

ZURICH, SWITZERLAND – March 2, 2026 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company at the Extraordinary General Meeting (“EGM”) on February 27, 2026. Both resolutions are prerequisites for the closing of the proposed business combination (the “Business Combination”) among VERAXA, Veraxa Biotech Hold

Benzinga · Mar 2, 2026

VERAXA Biotech Secures Shareholder Approval For Merger And New Share Issuance, Moving Closer To Business Combination Closing With Voyager

defenseworld.net · Dec 11, 2025

Contrasting Blaize (NASDAQ:BZAI) & Voyager Acquisition (NASDAQ:VACH)

Blaize (NASDAQ: BZAI - Get Free Report) and Voyager Acquisition (NASDAQ: VACH - Get Free Report) are both small-cap financial services companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability. Valuation and Earnings This table compares Blaize